Cancer Genetics, Inc. (CGIX) - Product Pipeline Analysis, 2013 Update


#182202

43pages

GlobalData

$ 750

In Stock


Cancer Genetics, Inc. (CGI) is a pharmaceutical company. The company offers DNA-based cancer diagnostics products and services. Its products include MatBA, UroGenRA, and FHACT. CGIs MatBA is a mature b-cell neoplasm array used in diagnosis and prognosis of non-Hodgkin lymphomas. The companys UroGenRA is an oligonucleotide array product that is developed to detect genomic copy number alterations with prognostic and diagnostic value in kidney, prostate and bladder cancers. Its FHACT is a FISH-based HPV-associated cancer test. The company provides clinical services such as test menu, complete program, and summation report. It collaborates with Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. CGI is headquartered in New Jersey, the US.

This report is a source for data, analysis and actionable intelligence on the Cancer Genetics, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Scope

  • Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
  • Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
  • Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
  • Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
  • Data on relevant clinical trials and product patent details, wherever applicable.
  • Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
  • Design and develop your product development, marketing and sales strategies.
  • Exploit M&A opportunities by identifying market players with the most innovative pipeline.
  • Develop market-entry and market expansion strategies.
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Develop competition strategies by identifying the status and likely launch of your competitors pipeline products through review of the clinical trials, stage and phase of development, etc.
  • Which are the next high-value products that your competitor would add in its portfolio? identify, understand and capitalize.
Table of Content

Table of Contents 2
List of Tables 4
List of Figures 5

Key Facts 6
Cancer Genetics, Inc. - Major Products and Services 7
Cancer Genetics, Inc. Pipeline Products by Equipment Type 8
Cancer Genetics, Inc. Pipeline Products by Development Stage 10
Cancer Genetics, Inc. Pipeline Products by Therapy Area 12
FHACT Test - Head and Neck Cancer 14
FHACT Test - Head and Neck Cancer Product Status 14
FHACT Test - Head and Neck Cancer Product Description 14
FReCaD Renal Cancer Test 15
FReCaD Renal Cancer Test Product Status 15
FReCaD Renal Cancer Test Product Description 15
FReCaD Renal Cancer Test Product Patent Details 15
LeukA - Leukemia 20
LeukA - Leukemia Product Status 20
LeukA - Leukemia Product Description 20
MatBA Diagnostic Test - Follicular Lymphoma 21
MatBA Diagnostic Test - Follicular Lymphoma Product Status 21
MatBA Diagnostic Test - Follicular Lymphoma Product Description 21
MatBA Diagnostic Test - Follicular Lymphoma Product Patent Details 21
MatBA Diagnostic Test - Mantle Cell Lymphoma 23
MatBA Diagnostic Test - Mantle Cell Lymphoma Product Status 23
MatBA Diagnostic Test - Mantle Cell Lymphoma Product Description 23
MatBA Diagnostic Test - Mantle Cell Lymphoma Product Patent Details 23
MatBA Diagnostic Test - Multiple Myeloma 25
MatBA Diagnostic Test - Multiple Myeloma Product Status 25
MatBA Diagnostic Test - Multiple Myeloma Product Description 25
MatBA Diagnostic Test - Multiple Myeloma Product Patent Details 25
Next-Gen DNA Sequencing Assay - Hematological Cancer 27
Next-Gen DNA Sequencing Assay - Hematological Cancer Product Status 27
Next-Gen DNA Sequencing Assay - Hematological Cancer Product Description 27
Next-Gen DNA Sequencing Assay - Prostate Cancer 28
Next-Gen DNA Sequencing Assay - Prostate Cancer Product Status 28
Next-Gen DNA Sequencing Assay - Prostate Cancer Product Description 28
UGenRA - Cervix 29
UGenRA - Cervix Product Status 29
UGenRA - Cervix Product Description 29
UGenRA - Endometrium 30
UGenRA - Endometrium Product Status 30
UGenRA - Endometrium Product Description 30
UGenRA - Ovary 31
UGenRA - Ovary Product Status 31
UGenRA - Ovary Product Description 31
UroGenRA - Bladder 32
UroGenRA - Bladder Product Status 32
UroGenRA - Bladder Product Description 32
UroGenRA - Prostate 33
UroGenRA - Prostate Product Status 33
UroGenRA - Prostate Product Description 33
Cancer Genetics, Inc. - Key Competitors 34
Cancer Genetics, Inc. - Key Employees 35
Cancer Genetics, Inc. - Locations And Subsidiaries 36
Head Office 36
Recent Developments 37
Cancer Genetics, Inc., Recent Developments 37
Dec 19, 2013: Cancer Genetics Strengthens Its Diagnostics Sales Team With Seasoned Industry Leader 37
Nov 13, 2013: Cancer Genetics, Inc. announces third quarter financial results 37
Nov 11, 2013: Cancer Genetics Announces Conference Call to Discuss Third Quarter Results 38
Nov 06, 2013: Cancer Genetics Granted Patent for Kidney Cancer Diagnosis & Typing Using a Proprietary Genomic Method 39
Oct 08, 2013: Cancer Genetics Will Open Precision Medicine Conference With Keynote Presentation 39
Oct 04, 2013: Cancer Genetics CEO Panna Sharma to Participate in Panel at BioNJ CEO Summit 40
Sep 09, 2013: Cancer Genetics Announces Upcoming Investor Conference Schedule 40
Sep 09, 2013: NextGxDx Adds Cancer Genetics to Genetic Testing Platform 40
Aug 23, 2013: RedChip Issues Research Profile on Cancer Genetics 41
Aug 05, 2013: Cancer Genetics Announces Second Quarter 2013 Financial Results 41

Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

Cancer Genetics, Inc., Key Facts 1
Cancer Genetics, Inc. Key Pipeline Products by Equipment Type 1
Cancer Genetics, Inc. Key Pipeline Products by Therapy Area 1
Cancer Genetics, Inc. Key Pipeline Products by Development Stage 1
Cancer Genetics, Inc., Key Facts 6
Cancer Genetics, Inc., Major Products and Services 7
Cancer Genetics, Inc. Number of Pipeline Products by Equipment Type 8
Cancer Genetics, Inc. Pipeline Products by Equipment Type 9
Cancer Genetics, Inc. Number of Pipeline Products by Development Stage 10
Cancer Genetics, Inc. Pipeline Products by Development Stage 11
Cancer Genetics, Inc. Number of Pipeline Products by Therapy Area 12
Cancer Genetics, Inc. Pipeline Products by Therapy Area 13
FHACT Test - Head and Neck Cancer - Product Status 14
FHACT Test - Head and Neck Cancer - Product Description 14
FReCaD Renal Cancer Test - Product Status 15
FReCaD Renal Cancer Test - Product Description 15
FReCaD Renal Cancer Test - Patent Details1 15
FReCaD Renal Cancer Test - Patent Details2 16
FReCaD Renal Cancer Test - Patent Details3 16
FReCaD Renal Cancer Test - Patent Details4 17
FReCaD Renal Cancer Test - Patent Details5 17
FReCaD Renal Cancer Test - Patent Details6 18
FReCaD Renal Cancer Test - Patent Details7 18
LeukA - Leukemia - Product Status 20
LeukA - Leukemia - Product Description 20
MatBA Diagnostic Test - Follicular Lymphoma - Product Status 21
MatBA Diagnostic Test - Follicular Lymphoma - Product Description 21
MatBA Diagnostic Test - Follicular Lymphoma - Patent Details1 21
MatBA Diagnostic Test - Mantle Cell Lymphoma - Product Status 23
MatBA Diagnostic Test - Mantle Cell Lymphoma - Product Description 23
MatBA Diagnostic Test - Mantle Cell Lymphoma - Patent Details1 23
MatBA Diagnostic Test - Multiple Myeloma - Product Status 25
MatBA Diagnostic Test - Multiple Myeloma - Product Description 25
MatBA Diagnostic Test - Multiple Myeloma - Patent Details1 25
Next-Gen DNA Sequencing Assay - Hematological Cancer - Product Status 27
Next-Gen DNA Sequencing Assay - Hematological Cancer - Product Description 27
Next-Gen DNA Sequencing Assay - Prostate Cancer - Product Status 28
Next-Gen DNA Sequencing Assay - Prostate Cancer - Product Description 28
UGenRA - Cervix - Product Status 29
UGenRA - Cervix - Product Description 29
UGenRA - Endometrium - Product Status 30
UGenRA - Endometrium - Product Description 30
UGenRA - Ovary - Product Status 31
UGenRA - Ovary - Product Description 31
UroGenRA - Bladder - Product Status 32
UroGenRA - Bladder - Product Description 32
UroGenRA - Prostate - Product Status 33
UroGenRA - Prostate - Product Description 33
Cancer Genetics, Inc., Key Employees 35
Cancer Genetics, Inc. Pipeline Products by Equipment Type 8
Cancer Genetics, Inc. Pipeline Products by Development Stage 10
Cancer Genetics, Inc. Pipeline Products by Therapy Area 12